Furthermore, there are several clinical trials recruiting patients using an alternative peptide-tag based CAR system sCAR (switchable CAR) with CD19-targeted adapter molecules (NCT04450069) as well as a d-domain based BCMA-targeted trial in multiple myeloma (NCT04155749). Here, TNFRSF17 is linked to plasma cell myeloma.